journal
https://read.qxmd.com/read/38459836/tucidinostat-plus-exemestane-as-a-neoadjuvant-in-early-stage-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-breast-cancer
#21
JOURNAL ARTICLE
Hongmeng Zhao, Dan Li, Qian Li, Bin Zhang, Chunhua Xiao, Ying Zhao, Jie Ge, Yue Yu, Yumian Jia, Xiaojing Guo, Xuchen Cao, Xin Wang
BACKGROUND: To assess the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer. METHODS: This prospective, open-label, single-arm phase II trial enrolled patients with stage II-III breast cancer with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative. Eligible patients received tucidinostat plus exemestane, and then breast-conserving surgery (BCS) or modified radical mastectomy...
March 9, 2024: Oncologist
https://read.qxmd.com/read/38452035/a-phase-ii-study-of-rucaparib-monotherapy-in-nonmetastatic-hormone-sensitive-prostate-cancer-demonstrating-brcaness-genotype-roar
#22
JOURNAL ARTICLE
Kamal Kant Sahu, Haoran Li, Vinay Mathew Thomas, Mallory Benson, Ken Boucher, Sumati Gupta, Manish Kohli, Umang Swami, Neeraj Agarwal, Benjamin L Maughan
BACKGROUND: Both germline and somatic BReast CAncer gene (BRCA) mutations are poor prognostic markers in men with localized or metastatic prostate cancer. For instance, men with these mutations often are diagnosed with prostate cancer earlier and develop metastatic disease earlier compared with those who do not harbor similar mutations. Patients with germline alterations typically have more advanced disease and shorter overall survival (Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer...
March 7, 2024: Oncologist
https://read.qxmd.com/read/38438322/plasma-ctdna-monitoring-of-a-ptch1-mutant-metastatic-adult-medulloblastoma-showing-a-durable-benefit-with-vismodegib
#23
JOURNAL ARTICLE
Santiago Cabezas-Camarero, Vanesa García-Barberán, Rebeca Pérez-Alfayate, María Elena Gómez Del Pulgar, Maria Nieves Cabrera-Martin, Isabel Casado-Fariñas, Pedro Pérez-Segura
Adult medulloblastoma (MB) is a rare disease affecting 0.6 persons per million adults over 19 years of age. The SHH-activated/TP53-wild type is the most common subtype, accounting for 60% of adult MBs, being characterized by mutations in PTCH1, SMO, or the TERT promoter. Several small studies demonstrate objective but short-lived responses to SMO inhibitors such as vismodegib or sonidegib. Like other oncogene-addicted solid tumors, detection of the corresponding drivers through liquid biopsy could aid in the molecular diagnosis and monitoring of the disease through less invasive procedures...
March 4, 2024: Oncologist
https://read.qxmd.com/read/38431782/integrating-patient-reported-outcomes-into-prognostication-in-gastroesophageal-cancer-results-of-a-population-based-retrospective-cohort-analysis
#24
JOURNAL ARTICLE
Thais Baccili Cury Megid, Divya Sharma, Zeynep Baskurt, Lucy Xiaolu Ma, Xin Wang, Carly C Barron, Raymond Woo-Jun Jang, Eric Xueyu Chen, Carol Jane Swallow, Aruz Mesci, Jonathan Yeung, Rebecca K S Wong, Savtaj Singh Brar, Patrick Veit-Haibach, John Kim, Yvonne Bach, Hiroko Aoyama, Elena Elimova
BACKGROUND: Patient-reported outcomes measures (PROM) are self-reflections of an individual's physical functioning and emotional well-being. The Edmonton Symptom Assessment Scale (ESAS) is a simple and validated PRO tool of 10 common symptoms and a patient-reported functional status (PRFS) measure. The prognostic value of this tool is unknown in patients with gastroesophageal cancer (GEC). In this study, we examined the association between the ESAS score and overall survival (OS) in patients with GEC, the prognostication difference between ESAS and Eastern Cooperative Oncology Group (ECOG), and assessed the correlation between PRFS and the physician-reported ECOG performance status (PS)...
March 2, 2024: Oncologist
https://read.qxmd.com/read/38431781/two-hematological-markers-predicting-the-efficacy-and-prognosis-of-neoadjuvant-chemotherapy-using-lobaplatin-against-triple-negative-breast-cancer
#25
JOURNAL ARTICLE
Cheng Wang, Qiyun Shi, Guozhi Zhang, Xiujuan Wu, Wenting Yan, Andi Wan, Siyi Xiong, Long Yuan, Hao Tian, Dandan Ma, Jun Jiang, Xiaowei Qi, Yi Zhang
BACKGROUND: Our previous work indicated that the addition of lobaplatin to combined therapy with taxane and anthracycline can improve the pathological complete response rate of neoadjuvant therapy for triple-negative breast cancer (TNBC) and lengthen long-term survival significantly, but the therapeutic markers of this regimen are unclear. METHODS: Eighty-three patients who met the inclusion criteria were included in this post hoc analysis. We analyzed the association between platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) before neoadjuvant chemotherapy with the efficacy and prognosis after treatment with docetaxel, epirubicin, and lobaplatin neoadjuvant chemotherapy regimen...
March 2, 2024: Oncologist
https://read.qxmd.com/read/38431780/treatment-and-prognosis-of-male-breast-cancer-a-multicentric-retrospective-study-over-11-years-in-the-czech-republic
#26
JOURNAL ARTICLE
Zuzana Bielcikova, Milos Holanek, Iveta Selingerova, Ondrej Sorejs, Iveta Kolarova, Renata Soumarova, Jan Proks, Lucie Reifova, Vlastimila Cmejlova, Lenka Linkova, Michaela Zabojnikova, Martina Chodacka, Lucie Janovska, Lenka Lisnerova, Karolina Kasparova, Denisa Pohankova, Lubos Petruzelka
PURPOSE: Male breast cancer (MBC) is a rare, but increasingly common disease, and lacks prospective studies. Collaborative efforts are needed to understand and address MBC, including its prognosis, in different countries. METHODS: We retrospectively reviewed the clinical, histopathological, and molecular-genetic characteristics, treatments, and survival outcomes of MBC diagnosed between 2007 and 2017 in the Czech Republic. Prognostic factors of overall survival (OS), recurrence-free interval (RFi), and breast cancer-specific mortality (BCSM) were analyzed and indirectly compared to international data...
March 2, 2024: Oncologist
https://read.qxmd.com/read/38417095/clinical-value-of-timely-targeted-therapy-for-patients-with-advanced-non-small-cell-lung-cancer-with-actionable-driver-oncogenes
#27
JOURNAL ARTICLE
Thomas Stricker, Neha Jain, Esprit Ma, Elaine Yu, Rongrong Wang, Robert Schuldt, Richard Price, Tania Szado, Jesse Sussell, Sarika Ogale, Victor Lin, Edward Arrowsmith, Dennis Slater, Daniel Vaena, Harry Staszewski, Bruno Fang, Lasika Seneviratne, Davey Daniel
BACKGROUND: A recent real-world study observed that 24% of patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADOs) initiated nontargeted therapies before biomarker test results became available. This study assessed the clinical impact of the timing of first-line (1L) targeted therapies (TTs) in aNSCLC. MATERIALS AND METHODS: This retrospective analysis of a nationwide electronic health record-derived deidentified database included patients aged ≥18 years diagnosed with aNSCLC with ADOs (ALK, BRAF, EGFR, RET, MET, ROS-1, and NTRK) from January 1, 2015, to October 18, 2022, by biomarker testing within 90 days after advanced diagnosis and received 1L treatment...
February 28, 2024: Oncologist
https://read.qxmd.com/read/38401173/real-world-clinical-performance-of-a-dna-based-comprehensive-genomic-profiling-assay-for-detecting-targetable-fusions-in-nonsquamous-nsclc
#28
JOURNAL ARTICLE
Philip C Mack, Rachel B Keller-Evans, Gerald Li, Katherine T Lofgren, Alexa B Schrock, Sally E Trabucco, Justin M Allen, Khaled Tolba, Geoffrey R Oxnard, Richard S P Huang
BACKGROUND: Genomic fusions are potent oncogenic drivers across cancer types and many are targetable. We demonstrate the clinical performance of DNA-based comprehensive genomic profiling (CGP) for detecting targetable fusions. MATERIALS AND METHODS: We analyzed targetable fusion genes in >450 000 tissue specimens profiled using DNA CGP (FoundationOne CDx, FoundationOne). Using a de-identified nationwide (US-based) non-small cell lung cancer (NSCLC) clinico-genomic database, we assessed outcomes in patients with nonsquamous NSCLC (NonSqNSCLC) who received matched therapy based on a fusion identified using DNA CGP...
February 24, 2024: Oncologist
https://read.qxmd.com/read/38394390/a-somatic-brca2-mutated-pancreatic-adenocarcinoma-with-sustained-exceptional-response-to-modified-folfirinox
#29
JOURNAL ARTICLE
Jacob K Jamison, Michael S May, Alexander G Raufi, Lyndon Luk, Winston Wong, Prabhjot S Mundi, Gulam A Manji
Homologous recombination repair (HRR) pathway deficiency opens multiple therapeutic avenues within pancreatic cancer. Patients with HRR deficiency-associated gene mutations such as BRCA1, BRCA2, and PALB2 are more susceptible to platinum-based chemotherapies and in those with somatic BRCA mutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associated with treatment and prevention of central nervous system metastases in long-term survivors of pancreatic cancer...
February 23, 2024: Oncologist
https://read.qxmd.com/read/38394385/adherence-to-treatment-and-follow-up-of-precancerous-cervical-lesions-in-ethiopia
#30
JOURNAL ARTICLE
Clara Yolanda Stroetmann, Muluken Gizaw, Rahel Alemayehu, Abigiya Wondimagegnehu, Friedemann Rabe, Pablo Santos, Bariki Mchome, Blandina Theophil Mmbaga, Adamu Addissie, Eva Johanna Kantelhardt
BACKGROUND: In Ethiopia, both incidence and mortality of cervical cancer are relatively high. Screening services, which were implemented during the past few years, are currently being expanded. The World Health Organization recommends patients with a positive VIA (visual inspection with acetic acid) result should immediately receive treatment followed by rescreening after 1 year as precancerous lesions can reoccur or become residential despite treatment. MATERIALS AND METHODS: Screening logbooks dating between 2017 and 2020 were retrospectively reviewed in 14 health facilities of Addis Ababa and Oromia region...
February 23, 2024: Oncologist
https://read.qxmd.com/read/38394384/extended-safety-and-tolerability-of-darolutamide-for-nonmetastatic-castration-resistant-prostate-cancer-and-adverse-event-time-course-in-aramis
#31
JOURNAL ARTICLE
Neal D Shore, Christian Gratzke, Susan Feyerabend, Patrick Werbrouck, Joan Carles, Egils Vjaters, Teuvo L J Tammela, David Morris, Jeanny B Aragon-Ching, Raoul S Concepcion, Urban Emmenegger, Neil Fleshner, Markus Grabbert, Vilnis Lietuvietis, Hakim Mahammedi, Felipe M Cruz, Adriano Paula, Christopher Pieczonka, Antti Rannikko, Martin Richardet, Glauco Silveira, Iris Kuss, Marie-Aude Le Berre, Frank Verholen, Toni Sarapohja, Matthew R Smith, Karim Fizazi
BACKGROUND: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are usually asymptomatic and seek treatments that improve survival but have a low risk of adverse events. Darolutamide, a structurally distinct androgen receptor inhibitor (ARi), significantly reduced the risk of metastasis and death versus placebo in ARAMIS. We assessed the extended safety and tolerability of darolutamide and the time-course profile of treatment-emergent adverse events (TEAEs) related to ARis and androgen-suppressive treatment...
February 23, 2024: Oncologist
https://read.qxmd.com/read/38387031/palliative-care-interventions-and-end-of-life-care-for-patients-with-metastatic-breast-cancer-a-multicentre-analysis
#32
JOURNAL ARTICLE
Elisabeth Lucchi, Frédérique Berger, Maude Milder, Jean-Marie Commer, Sophie Morin, Geraldine Capodano, Muriel Thomaso, Anne Fogliarini, Nathalie Bremaud, Aline Henry, Benedicte Mastroianni, Gisele Chvetzoff, Carole Bouleuc
BACKGROUND: The aim of this study was to describe the implementation of integrated palliative care (PC) and the intensity of care in the last 3 months before death for patients with metastatic breast cancer. MATERIALS AND METHODS: We conducted a multicentric study of all adult patients with metastatic breast cancer who died over a 4-month period. Complete data were collected and checked from clinical records, including PC interventions and criteria regarding EOL care aggressiveness...
February 22, 2024: Oncologist
https://read.qxmd.com/read/38381694/adrenocortical-carcinomas-molecular-pathogenesis-treatment-options-and-emerging-immunotherapy-and-targeted-therapy-approaches
#33
JOURNAL ARTICLE
Divya Chukkalore, Kira MacDougall, Viraj Master, Mehmet Asim Bilen, Bassel Nazha
Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy in the advanced setting with poor prognosis. This narrative review provides an overview of the epidemiology of ACC and its molecular pathogenesis with a summary of the main involved signaling pathways. We then provide an update on the clinical presentation, diagnosis, and current management strategies of both localized and metastatic disease from a multidisciplinary perspective. We highlight the debate around the use of mitotane in the adjuvant setting and review the use of combination chemotherapy with etoposide, doxorubicin, and cisplatin...
February 21, 2024: Oncologist
https://read.qxmd.com/read/38381603/anaplastic-lymphoma-kinase-alk-inhibitors-show-activity-in-colorectal-cancer-with-alk-rearrangements-case-series-and-literature-review
#34
JOURNAL ARTICLE
Tingting Hu, Jinbo Zhan, Li Li, Yan He, Yun Lin, Jingru Wang, Haiming Yu, Jianping Xiong, Ziling Fang, Jun Deng, Shanshan Huang, Xiaojun Xiang
Anaplastic lymphoma kinase (ALK) rearrangement is a well-known driver oncogene detected in approximately 5% of non-small cell lung cancer. However, ALK rearrangement is much less frequent in other solid tumors outside the lungs, such as colorectal cancer (CRC); thus, the optimal management of CRC with ALK rearrangements has yet to be established. In this report, we describe 2 cases of ALK-positive CRC, both of which benefited from ALK tyrosine kinase inhibitor (ALK-TKI) therapy. Case 1 was a postoperative patient with poorly differentiated colon adenocarcinoma, who was diagnosed with metastatic relapse shortly after surgery...
February 21, 2024: Oncologist
https://read.qxmd.com/read/38377176/atezolizumab-plus-carboplatin-and-etoposide-in-patients-with-untreated-extensive-stage-small-cell-lung-cancer-interim-results-of-the-mauris-phase-iiib-trial
#35
JOURNAL ARTICLE
Emilio Bria, Floriana Morgillo, Marina Chiara Garassino, Fortunato Ciardiello, Andrea Ardizzoni, Alessio Stefani, Francesco Verderame, Alessandro Morabito, Antonio Chella, Giuseppe Tonini, Marina Gilli, Ester Del Signore, Rossana Berardi, Manlio Mencoboni, Alessandra Bearz, Angelo Delmonte, Marta Rita Migliorino, Cesare Gridelli, Antonio Pazzola, Manuela Iero, Filippo De Marinis
BACKGROUND: MAURIS is an Italian multicenter, open-label, phase IIIb ongoing trial, aiming at evaluating the safety and effectiveness of atezolizumab + carboplatin/etoposide in patients with newly diagnosed, extensive-stage small-cell lung cancer (ES-SCLC). The primary objective is the safety evaluation. MATERIALS AND METHODS: Patients received atezolizumab + carboplatin/etoposide Q3W for 4-6 cycles in the induction phase, followed by atezolizumab maintenance Q3W...
February 20, 2024: Oncologist
https://read.qxmd.com/read/38366907/association-between-homologous-recombination-repair-defect-status-and-long-term-prognosis-of-early-her2-low-breast-cancer-a-retrospective-cohort-study
#36
JOURNAL ARTICLE
Jiayi Chen, Yingying Zhu, Wei Wu, Yaqi Xu, Wenqian Yang, Li Ling, Qun Lin, Shijie Jia, Yuan Xia, Zihao Liu, Yaping Yang, Chang Gong
BACKGROUND: As a newly identified subtype of HER2-negative tumors associated with a less favorable prognosis, it remains crucial to evaluate potential prognostic and predictive factors, particularly non-invasive biomarkers, for individuals with human epidermal growth factor 2 (HER2) low early-stage breast cancer (EBC). Multiple investigations have highlighted that HER2-negative patients with EBC exhibiting high homologous recombination deficiency (HRD) scores display lower rates of pathological complete response (PCR) to neoadjuvant chemotherapy (NAC)...
February 16, 2024: Oncologist
https://read.qxmd.com/read/38366886/apatinib-plus-toripalimab-anti-pd1-therapy-as-second-line-therapy-in-patients-with-advanced-gastric-or-esophagogastric-junction-cancer-results-from-a-randomized-open-label-phase-ii-study
#37
JOURNAL ARTICLE
Qing Wei, Xiaoqing Xu, Jingjing Li, Chang Wang, Weijun Chen, Yanru Xie, Cong Luo, Lei Chen, Jiadong Chu, Wei Wu, Zhe Han, Yanlian Yang, Zhiyuan Hu, Qi Xu, Jieer Ying
BACKGROUND: This study aimed to assess the activity of apatinib plus toripalimab in the second line for patients with advanced gastric or esophagogastric junction cancer (GC/EGJC). METHODS: In this open-label, phase II, randomized trial, patients with advanced GC/EGJC who progressed after first-line chemotherapy were enrolled and received 250 mg apatinib per day plus 240 mg toripalimab on day 1 per 3 weeks (arm A) or physician's choice of chemotherapy (PC, arm B)...
February 16, 2024: Oncologist
https://read.qxmd.com/read/38366864/efficacy-and-safety-of-trifluridine-tipiracil-containing-combinations-in-colorectal-cancer-and-other-advanced-solid-tumors-a-systematic-review
#38
JOURNAL ARTICLE
Kohei Shitara, Alfred Falcone, Marwan G Fakih, Ben George, Raghav Sundar, Sandip Ranjan, Eric Van Cutsem
We performed a systematic literature review to identify and summarize data from studies reporting clinical efficacy and safety outcomes for trifluridine/tipiracil (FTD/TPI) combined with other antineoplastic agents in advanced cancers, including metastatic colorectal cancer (mCRC). We conducted a systematic search on May 29, 2021, for studies reporting one or more efficacy or safety outcome with FTD/TPI-containing combinations. Our search yielded 1378 publications, with 38 records meeting selection criteria: 35 studies of FTD/TPI-containing combinations in mCRC (31 studies second line or later) and 3 studies in other tumor types...
February 16, 2024: Oncologist
https://read.qxmd.com/read/38366856/comparing-drug-shortages-experienced-by-institutions-with-national-metrics
#39
JOURNAL ARTICLE
Austin Pytlowany, Noah Leja, Stanley Kent
Drug shortages have increasingly posed challenges to providers, pharmacists, and patients for more than 20 years. Regardless of the underlying causes, for which there does not appear to be a solution in sight, healthcare providers and patients must deal with the consequences. There is often conflicting and confusing information published that confuses everyone. This article describes the reasons for conflicting information from different sources.
February 16, 2024: Oncologist
https://read.qxmd.com/read/38349736/impact-of-increasing-pd-l1-levels-on-outcomes-to-pd-1-pd-l1-inhibition-in-patients-with-nsclc-a-pooled-analysis-of-11-prospective-clinical-trials
#40
JOURNAL ARTICLE
Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti, Pallavi Mishra-Kalyani, Shenghui Tang, Julia A Beaver, Mark M Awad
BACKGROUND: Programmed death ligand 1 (PD-L1) expression is recognized as a key biomarker in the treatment of non-small cell lung cancer (NSCLC) with anti-PD(L)1 inhibitors. Previous work has highlighted that outcomes in patients with NSCLC treated with anti-PD(L)1 inhibitors generally improve with increasing PD-L1 expression. The objectives of these analyses are to quantitate the effect of PD-L1 expression on outcomes, to characterize the potentially nonlinear relationship between PD-L1 expression and outcomes, and to assess potential differences in these relationships across subgroups...
February 13, 2024: Oncologist
journal
journal
20207
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.